COSMO Pharmaceuticals SA Net Asset Quality Index
COSMO Pharmaceuticals SA net asset quality index. COSMO Pharmaceuticals SA (0RGI) has a Net Asset Quality Index of 82.5% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of £695.64 Million minus total liabilities of £121.91 Million yields net assets of £573.73 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check 0RGI operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of COSMO Pharmaceuticals SA (2004–2025)
Net asset quality index of COSMO Pharmaceuticals SA from 2004 to 2025. This chart shows how COSMO Pharmaceuticals SA's Net Asset Quality Index has evolved across 22 annual periods from 2004 to 2025. As of June 2026, the index stands at 82.5%, representing net assets of £573.73 Million against total assets of £695.64 Million GBP. See COSMO Pharmaceuticals SA (0RGI) net assets for net asset value and shareholders' equity analysis.
COSMO Pharmaceuticals SA Net Asset Quality Index by Year (2004–2025)
COSMO Pharmaceuticals SA net asset quality index by year from 2004 to 2025. The table below presents the year-by-year Net Asset Quality Index for COSMO Pharmaceuticals SA from 2004 to 2025, covering 22 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 0RGI company net worth.
| Year | Quality Index | Net Assets (GBP) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 79.8% | £488.80 Million | £612.16 Million | £123.36 Million | ▲ +1.8 pp |
| 2024 | 78.1% | £505.09 Million | £646.77 Million | £141.68 Million | ▲ +0.6 pp |
| 2023 | 77.4% | £429.04 Million | £553.98 Million | £124.94 Million | ▲ +16.4 pp |
| 2022 | 61.1% | £463.79 Million | £759.59 Million | £295.80 Million | ▼ -2.6 pp |
| 2021 | 63.6% | £512.68 Million | £805.56 Million | £292.88 Million | ▼ -3.5 pp |
| 2020 | 67.1% | £400.12 Million | £596.16 Million | £196.04 Million | ▼ -0.2 pp |
| 2019 | 67.3% | £393.73 Million | £585.16 Million | £191.43 Million | ▼ -3.8 pp |
| 2018 | 71.1% | £444.85 Million | £625.69 Million | £180.83 Million | ▼ -23.3 pp |
| 2017 | 94.4% | £470.12 Million | £497.97 Million | £27.86 Million | ▲ +0.7 pp |
| 2016 | 93.7% | £415.56 Million | £443.47 Million | £27.92 Million | ▲ +1.5 pp |
| 2015 | 92.2% | £403.65 Million | £437.94 Million | £34.30 Million | ▲ +24.7 pp |
| 2014 | 67.5% | £152.29 Million | £225.62 Million | £73.33 Million | ▼ -23.1 pp |
| 2013 | 90.6% | £220.16 Million | £243.00 Million | £22.85 Million | ▲ +8.5 pp |
| 2012 | 82.1% | £150.41 Million | £183.30 Million | £32.89 Million | ▲ +0.8 pp |
| 2011 | 81.3% | £63.43 Million | £78.04 Million | £14.60 Million | ▲ +17.7 pp |
| 2010 | 63.6% | £58.37 Million | £91.83 Million | £33.46 Million | ▼ -20.1 pp |
| 2009 | 83.7% | £59.80 Million | £71.46 Million | £11.67 Million | ▲ +8.8 pp |
| 2008 | 74.8% | £43.24 Million | £57.77 Million | £14.53 Million | ▲ +0.4 pp |
| 2007 | 74.4% | £35.15 Million | £47.23 Million | £12.08 Million | ▲ +51.8 pp |
| 2006 | 22.6% | £5.34 Million | £23.61 Million | £18.27 Million | ▲ +20.4 pp |
| 2005 | 2.2% | £631.00K | £28.21 Million | £27.58 Million | ▲ +6.0 pp |
| 2004 | -3.8% | £-880.00K | £23.46 Million | £24.34 Million | — |